Ganetespib: research and clinical development

por Jhaveri, Komal, Modi, Shanu
Publicado 2015

HER2 breast cancer therapies: a review

por Murphy, Conleth G, Modi, Shanu
Publicado 2009

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

por Ferraro, Emanuela, Drago, Joshua Z., Modi, Shanu
Publicado 2021

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan

por Moss, Nelson S, Tosi, Umberto, Santomasso, Bianca D, Beal, Kathryn, Modi, Shanu
Publicado 2022

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

por Yang, Charlie, Brezden-Masley, Christine, Joy, Anil Abraham, Sehdev, Sandeep, Modi, Shanu, Simmons, Christine, Henning, Jan-Willem
Publicado 2023

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

por Moss, Nelson S., Singh, Jolene M., Reiner, Anne S., Drago, Joshua Z., Modi, Shanu, Seidman, Andrew D., Chandarlapaty, Sarat, Ross, Dara S.
Publicado 2023

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

por Krop, Ian E., Modi, Shanu, LoRusso, Patricia M., Pegram, Mark, Guardino, Ellie, Althaus, Betsy, Lu, Dan, Strasak, Alexander, Elias, Anthony
Publicado 2016

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

por Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Publicado 2013

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients

por Gu, Stephanie, Dusza, Stephen, Quigley, Elizabeth, Haliasos, Helen, Markova, Alina, Marchetti, Michael, Moy, Andrea, Dang, Chau, Modi, Shanu, Lake, Diana, Noor, Sarah, Lacouture, Mario
Publicado 2023

Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer

por Beylergil, Volkan, Morris, Patrick G., Smith-Jones, Peter M., Modi, Shanu, Solit, David, Hudis, Clifford A., Lu, Yang, O’Donoghue, Joseph, Lyashchenko, Serge K., Carrasquillo, Jorge A., Larson, Steven M., Akhurst, Timothy J.
Publicado 2013

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

por Jhaveri, Komal, Wang, Rui, Teplinsky, Eleonora, Chandarlapaty, Sarat, Solit, David, Cadoo, Karen, Speyer, James, D’Andrea, Gabriella, Adams, Sylvia, Patil, Sujata, Haque, Sofia, O’Neill, Tara, Friedman, Kent, Esteva, Francisco J., Hudis, Clifford, Modi, Shanu
Publicado 2017

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

por Modi, Shanu, Park, Haeseong, Murthy, Rashmi K., Iwata, Hiroji, Tamura, Kenji, Tsurutani, Junji, Moreno-Aspitia, Alvaro, Doi, Toshihiko, Sagara, Yasuaki, Redfern, Charles, Krop, Ian E., Lee, Caleb, Fujisaki, Yoshihiko, Sugihara, Masahiro, Zhang, Lin, Shahidi, Javad, Takahashi, Shunji
Publicado 2020

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

por Ferraro, Emanuela, Singh, Jasmeet, Patil, Sujata, Razavi, Pedram, Modi, Shanu, Chandarlapaty, Sarat, Barrio, Andrea V., Malani, Rachna, Mellinghoff, Ingo K., Boire, Adrienne, Wen, Hannah Y., Brogi, Edi, Seidman, Andrew D., Norton, Larry, Robson, Mark E., Dang, Chau T.
Publicado 2022

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases

por Page, David B., Beal, Kathryn, Linch, Stefanie N., Spinelli, Kateri J., Rodine, Micaela, Halpenny, Darragh, Modi, Shanu, Patil, Sujata, Young, Robert J., Kaley, Thomas, Merghoub, Taha, Redmond, David, Wong, Phillip, Barker, Christopher A., Diab, Adi, Norton, Larry, McArthur, Heather L.
Publicado 2022

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metast...

por Iyengar, Neil M., Smyth, Lillian M., Lake, Diana, Gucalp, Ayca, Singh, Jasmeet C., Traina, Tiffany A., DeFusco, Patricia, Fornier, Monica N., Goldfarb, Shari, Jhaveri, Komal, Modi, Shanu, Troso-Sandoval, Tiffany, Patil, Sujata, Ulaner, Gary A., Jochelson, Maxine, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Publicado 2019

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

por Jerusalem, Guy, Park, Yeon Hee, Yamashita, Toshinari, Hurvitz, Sara A., Modi, Shanu, Andre, Fabrice, Krop, Ian E., Gonzàlez Farré, Xavier, You, Benoit, Saura, Cristina, Kim, Sung-Bae, Osborne, Cynthia R., Murthy, Rashmi K., Gianni, Lorenzo, Takano, Toshimi, Liu, Yali, Cathcart, Jillian, Lee, Caleb, Perrin, Christophe
Publicado 2022

Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation

por Rodina, Anna, Xu, Chao, Digwal, Chander S., Joshi, Suhasini, Patel, Yogita, Santhaseela, Anand R., Bay, Sadik, Merugu, Swathi, Alam, Aftab, Yan, Pengrong, Yang, Chenghua, Roychowdhury, Tanaya, Panchal, Palak, Shrestha, Liza, Kang, Yanlong, Sharma, Sahil, Almodovar, Justina, Corben, Adriana, Alpaugh, Mary L., Modi, Shanu, Guzman, Monica L., Fei, Teng, Taldone, Tony, Ginsberg, Stephen D., Erdjument-Bromage, Hediye, Neubert, Thomas A., Manova-Todorova, Katia, Tsou, Meng-Fu Bryan, Young, Jason C., Wang, Tai, Chiosis, Gabriela
Publicado 2023